Compounds reported to perpetrate CYP2C induction-based DDIs also perpetrate CYP3A4 induction-based DDIs
| Victim | Perpetrator (Oral) | % Change AUC | Victim Dose | Perpetrator Dose | References |
|---|---|---|---|---|---|
| Simvastatin CYP3A in vivo probe | Bosentan | −34.4 | 40 mg (5.5 days) | 125 mg (5.5 days) | (Dingemanse et al., 2003) |
| Simvastatin CYP3A in vivo probe | Carbamazepine | −74.5 | 80 mg | 300 mg (14 days) | (Ucar et al., 2004) |
| Simvastatin CYP3A in vivo probe | Rifampicin | −91.0 | 40 mg | 600 mg (9 days) | (Chung et al., 2006) |
| Simvastatin CYP3A in vivo probe | Rifampicin | −86.1 | 40 mg | 600 mg (5 days) | (Kyrklund et al., 2000) |
| Simvastatin CYP3A in vivo probe | Troglitazone | −37.7 | 40 mg (10 days) | 400 mg (24 days) | (Prueksaritanont et al., 2001) |
| Sildenafil CYP3A in vivo Probe | Bosentan | −69.0 | 100 mg | 62–125 mg (8 wk) | (Paul et al., 2005) |
| Midazolam CYP3A in vivo probe | Rifampicin | −98.4 | 7.5 mg | 600 mg (6 days) | (Link et al., 2008) |